🔍

GPTHEALTH - GPT Healthcare

📊 NSE: GPTHEALTH 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:33

📢 Recent Corporate Announcements

GPT Healthcare to Participate in Bharat Connect Conference on March 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Mar 2026, 11:27 AM

GPT Healthcare Limited has scheduled a virtual group meeting with institutional investors and fund managers on March 10, 2026, at 2:00 PM IST. The company will be participating in the 'Bharat Connect Conference: Rising Stars - March 2026' event. Discussions will be based on the previously released Q3FY26 investor presentation and other publicly available information. No unpublished price sensitive information is intended to be discussed during this session.

Virtual group meeting scheduled for Tuesday, March 10, 2026, at 2:00 PM IST
Participation in the 'Bharat Connect Conference: Rising Stars' for institutional investors
Company will utilize the existing Q3FY26 (December 2025) investor presentation
Compliance with Regulation 30(6) of SEBI Listing Obligations and Disclosure Requirements

💡 Investors should monitor the company's website for any post-conference transcripts or presentations that may offer additional qualitative insights into management's growth strategy.

GPT Healthcare Schedules Institutional Investor Meetings in Mumbai for March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 01:56 PM

GPT Healthcare Limited (GPTHEALTH) has announced a series of physical meetings with institutional investors and analysts scheduled for March 6, 2026. The meetings will take place in Mumbai between 10:30 A.M. and 5:30 P.M. in both one-on-one and group formats. Management will utilize the existing Q3FY26 investor presentation for discussions, ensuring no unpublished price-sensitive information is disclosed. This move reflects the company's ongoing commitment to transparent investor relations.

Physical investor meetings scheduled for Friday, March 6, 2026, in Mumbai.
Interaction window set between 10:30 A.M. and 5:30 P.M. for group and individual sessions.
Discussions to be based on the Q3FY26 (December 2025) presentation already in the public domain.
The meeting is conducted under Regulation 30(6) of SEBI LODR Regulations, 2015.

💡 This is a routine disclosure; investors should review the Q3FY26 presentation to understand the current business trajectory discussed with institutional players.

GPT Healthcare Q3 FY26: Revenue Grows 16.8% YoY; Raipur Facility Nears EBITDA Breakeven

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 04:08 PM

GPT Healthcare reported a 12.12% YoY revenue growth for 9M FY26, reaching ₹350.5 crores, with EBITDA margins stable at 18.58%. The company is seeing steady operational improvements, with occupancy (excluding the new Raipur facility) rising to 55% and ARPOB standing at ₹38,797. A key highlight is the Raipur facility, which reduced its quarterly EBITDA loss to ₹2.5 crores and is expected to break even within the next six months. Management remains committed to expanding its capacity to 1,000 beds by 2027, with the Jamshedpur project currently on track.

9M FY26 Revenue grew 12.12% YoY to ₹350.5 crores, while Q3 revenue surged 16.81% YoY.
EBITDA for 9M FY26 stood at ₹65.1 crores with an 18.58% margin; PAT was ₹27.6 crores.
Raipur facility EBITDA loss narrowed to ₹2.5 crores in Q3, with monthly breakeven expected in 6 months.
Salt Lake hospital occupancy improved to 63%, supported by over 750 robotic-enabled surgical procedures.
Company on track to reach 1,000-bed capacity by 2027, including the upcoming 150-bed Jamshedpur facility.

💡 Investors should monitor the Raipur facility's path to profitability over the next two quarters as it will significantly boost overall margins. The company remains a strong growth play in the underserved Eastern India healthcare market.

GPT Healthcare Releases Q3 & 9MFY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 03 Feb 2026, 03:37 PM

GPT Healthcare Limited has made the audio recording of its Q3 and 9MFY26 earnings conference call available to the public. The call, held on February 3, 2026, discussed the company's un-audited financial performance for the quarter and nine-month period ending December 31, 2025. Management engaged with institutional investors and analysts regarding operational trends and financial metrics. The company explicitly stated that no unpublished price-sensitive information (UPSI) was disclosed during the interaction.

Audio recording of the Q3 FY26 earnings call is now accessible via the company's website.
The call focused on financial results for the nine-month period ended December 31, 2025.
The session was conducted on February 3, 2026, at 10:00 AM IST.
Compliance filing confirms no unpublished price-sensitive information was shared during the meet.

💡 Investors should listen to the recording to gain insights into management's commentary on hospital margins and patient volume growth. This is a routine disclosure that provides qualitative context to the previously released financial numbers.

GPT Healthcare Q3 Revenue Up 17% to ₹122 Cr; PAT Declines 23.5% Amid Margin Pressure

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 02 Feb 2026, 05:04 PM

GPT Healthcare reported a 16.81% YoY increase in Q3 FY26 revenue to ₹121.6 crore, supported by higher patient volumes and a stronger specialty mix. However, the company faced significant margin contraction, with EBITDA margins falling to 18.20% from 22.23% in the previous year's quarter. Consequently, Profit After Tax (PAT) for Q3 FY26 declined by 23.5% YoY to ₹9.4 crore. For the nine-month period (9M FY26), revenue grew 12.12% to ₹350.5 crore, while PAT fell 25.32% to ₹27.6 crore, reflecting the impact of scaling new facilities like Raipur.

Q3 FY26 Total Revenue grew 16.81% YoY to ₹121.6 crore, while 9M FY26 revenue rose 12.12% to ₹350.5 crore.
Profit After Tax (PAT) for Q3 FY26 declined 23.5% YoY to ₹9.4 crore from ₹12.1 crore.
EBITDA margins contracted to 18.20% in Q3 FY26 compared to 22.23% in the corresponding quarter last year.
Average Revenue Per Occupied Bed (ARPOB) for 9M FY26 stood at ₹38,797 with an overall occupancy of 45%.
Company completed 750+ robotic surgeries at ILS Salt Lake and commissioned CTVS at ILS-Dum Dum.

💡 Investors should be cautious as the sharp decline in profitability and margins may weigh on the stock price in the short term. Monitor the ramp-up of the Raipur facility and the progress of the Jamshedpur project to see if operating leverage improves margins in future quarters.

GPT Healthcare Q3 Revenue Grows 16.8% to ₹121.6 Cr; PAT Declines 23.5% on Expansion Costs

🔵 WATCH ⭐ 7/10

EARNINGS 📅 02 Feb 2026, 04:59 PM

GPT Healthcare reported a 16.8% YoY revenue growth in Q3 FY26, reaching ₹121.6 Cr, supported by a 6% increase in ARPOB to ₹38,797. However, profitability faced headwinds due to the commissioning of the new Raipur facility, leading to a 23.5% YoY decline in Q3 PAT to ₹9.4 Cr. While overall network occupancy was 45%, mature hospitals showed resilience with occupancy improving marginally to 55%. The company remains focused on its 1,000-bed target by 2027, with the 150-bed Jamshedpur project currently in the planning phase.

Revenue for 9M FY26 increased 12.1% YoY to ₹350.5 Cr, while Q3 revenue rose 16.8% to ₹121.6 Cr.
Q3 EBITDA margin contracted to 18.2% from 22.2% YoY, with PAT falling 23.5% to ₹9.4 Cr.
ARPOB grew 6% YoY to ₹38,797, reflecting strengthened clinical offerings and specialty mix.
Raipur facility (158 beds) is scaling up after commissioning in Q1 FY26, impacting current margins.
Successfully performed 750+ robotic surgeries and launched CTVS services at the Dum Dum facility.

💡 Investors should monitor the ramp-up and break-even timeline of the Raipur hospital, as its initial losses are currently weighing on consolidated margins. The long-term investment thesis remains intact based on the company's aggressive expansion toward a 1,000-bed capacity in the underserved Eastern India market.

GPT Healthcare Q3FY26 Revenue up 17.5% YoY to ₹120 Cr; PAT drops 23.5% to ₹9.37 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 04:38 PM

GPT Healthcare reported a 17.5% YoY growth in revenue from operations to ₹120.16 crore for Q3FY26. However, net profit declined significantly by 23.5% YoY to ₹9.37 crore, primarily due to a sharp rise in operating and depreciation expenses. On a nine-month basis, while revenue grew to ₹346.18 crore, profit after tax fell from ₹37.03 crore to ₹27.65 crore. The company's margins were pressured by a 29% YoY increase in other expenses and a 52% jump in depreciation costs.

Revenue from operations grew 17.5% YoY to ₹12,015.81 lakhs in Q3FY26.
Net Profit (PAT) declined by 23.5% YoY to ₹936.83 lakhs from ₹1,224.61 lakhs in the same quarter last year.
Other expenses surged 28.9% YoY to ₹5,448.77 lakhs, significantly impacting operating margins.
Depreciation and amortization expenses increased by 52.3% YoY to ₹710.99 lakhs.
Nine-month (9MFY26) PAT stands at ₹2,765.45 lakhs, down 25.3% compared to ₹3,703.17 lakhs in 9MFY25.

💡 Investors should exercise caution as the company is experiencing significant margin compression despite healthy top-line growth. It is critical to monitor management's explanation for the surge in 'Other expenses' and the impact of new capacity on depreciation.

GPT Healthcare Schedules Q3 & 9MFY26 Earnings Call for February 3, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 27 Jan 2026, 09:03 PM

GPT Healthcare Limited has announced an earnings conference call scheduled for February 3, 2026, at 10:00 AM IST. The management will discuss the un-audited financial results for the third quarter and nine-month period ended December 31, 2025. Key participants include Group CFO Atul Tantia and Executive Director Anurag Tantia, who will provide commentary on the company's operational and financial performance.

Earnings conference call scheduled for February 3, 2026, at 10:00 AM IST.
Discussion to focus on Q3 and 9MFY26 financial results ending December 31, 2025.
Top management including Group CFO and Executive Director will be present for the call.
Universal dial-in numbers provided are +91 22 6280 1550 and +91 22 7115 8378.

💡 Investors should monitor the call for management commentary on hospital occupancy rates and future expansion plans in the healthcare sector.

GPT Healthcare Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 06:13 PM

GPT Healthcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. For the quarter ended December 31, 2025, the company's Registrar and Transfer Agent, MUFG Intime India Private Limited, confirmed that no requests for dematerialization or rematerialization of shares were received. This is a standard administrative filing required by all listed entities in India to maintain accurate shareholding records. The filing indicates regular adherence to regulatory reporting timelines.

Compliance certificate submitted for the quarter ended December 31, 2025.
Registrar MUFG Intime India Private Limited confirmed zero demat or remat requests during the quarter.
Filing adheres to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
The document confirms the company's share records are in order with the depositories.

💡 No action is required as this is a routine regulatory disclosure. Investors should continue to monitor the company's operational performance and upcoming quarterly financial results.

GPT Healthcare Announces Trading Window Closure from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 03:24 PM

GPT Healthcare Limited has announced the closure of its trading window for designated persons starting January 1, 2026. This is a standard regulatory procedure ahead of the declaration of the company's un-audited financial results for the third quarter ending December 31, 2025. The trading window will remain closed until 48 hours after the financial results are officially announced. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure begins on Thursday, January 1, 2026.
Closure is in anticipation of Q3 FY26 financial results for the period ending December 31, 2025.
The window will reopen 48 hours after the results are declared to the exchanges.
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory filing and does not impact the company's fundamentals. Investors should monitor for the upcoming announcement of the Q3 result date to assess financial performance.

GPT Healthcare Appoints MUFG Intime India for Investor Relations Advisory Services

🟢 POSITIVE ⭐ 3/10

OTHER 📅 26 Dec 2025, 01:00 PM

GPT Healthcare Limited has appointed MUFG Intime India Private Ltd as its Investor Relations (IR) agency, effective January 1, 2026. This strategic move is designed to enhance the company's visibility in capital markets and improve transparency with shareholders. Along with the appointment, the company has designated a specific email address, ir@gptgroup.co.in, for all investor-related queries. This administrative update reflects management's commitment to better market engagement and professional communication.

Appointment of MUFG Intime India Private Ltd as IR agency effective January 1, 2026
Strategic focus on strengthening investor communication and capital market visibility
Designation of a new dedicated email ID (ir@gptgroup.co.in) for investor queries
Compliance with Regulation 30 of SEBI (LODR) Regulations, 2015

💡 No immediate action is required as this is a routine administrative update. Investors should look for improved disclosure quality and more frequent market interactions following this appointment.

View All GPTHEALTH Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Revenue from operations grew by 11% YoY in H1 FY26 to INR 226 Cr, compared to INR 204 Cr in H1 FY25. Q2 FY26 revenue grew by 12.5% YoY to INR 118.9 Cr. The growth is primarily driven by healthcare services across in-patient and out-patient departments.

Geographic Revenue Split

Revenue is highly concentrated in West Bengal, Tripura, and Raipur (Chhattisgarh). West Bengal and Tripura are the primary contributors, though specific percentage splits per state are not disclosed.

Profitability Margins

PAT margin stood at 8% in H1 FY26 (INR 18.3 Cr), a decline from 11.4% in H1 FY25. FY25 PAT margin was 12.0% (INR 50 Cr). The decline in H1 FY26 is attributed to higher depreciation and finance costs associated with new hospital commissioning.

EBITDA Margin

EBITDA margin was 18.8% in H1 FY26 (INR 43 Cr), down from 22.3% in H1 FY25. This 350 bps compression is largely due to an operating loss of INR 3-4 Cr at the newly commissioned Raipur hospital which is yet to reach breakeven.

Capital Expenditure

The company has planned a capital expenditure of INR 50 Cr over the medium term for hospitals in Ranchi and Raipur. Historical fresh issue proceeds of INR 40 Cr in February 2024 were used for debt prepayment and corporate purposes.

Credit Rating & Borrowing

CRISIL has assigned a 'Stable' outlook. Borrowing costs are supported by low gearing (0.4 time in 2023) and low bank limit utilization of 4%. Interest coverage remains healthy despite finance costs rising to INR 3.80 Cr in H1 FY26 from INR 1.6 Cr in H1 FY25.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmacy drugs, and surgical implants represent the primary variable costs, categorized under 'Other expenses' which stood at INR 102.3 Cr in H1 FY26 (45% of revenue).

Capacity Expansion

Current installed capacity increased to 719 beds in H1 FY26 from 561 beds in FY25. Planned expansion includes a new asset-light hospital in Ranchi expected by FY2027-28.

Raw Material Costs

Other expenses (including medical consumables) increased to 45.2% of revenue in H1 FY26 from 42.6% in H1 FY25. Procurement is managed through internal controls to sustain operating margins between 21-22% in mature units.

Manufacturing Efficiency

Bed occupancy rate was 44.70% in H1 FY26, down from 53.76% in H1 FY25, due to the addition of new capacity at Raipur. Average Length of Stay (ALOS) improved to 3.49 days from 3.51 days YoY.

📈 Strategic Growth

Expected Growth Rate

11%

Growth Strategy

Growth will be achieved through the ramp-up of the Raipur hospital, which is expected to breakeven monthly by the 13th-14th month at 25% occupancy. Future growth is anchored on the Ranchi hospital (FY28) and increasing ARPOB (which grew from INR 29,671 to INR 32,947 in FY24) by launching new medical specialties.

Products & Services

Healthcare services including In-patient (IPD) treatments, Out-patient (OPD) consultations, surgical procedures, and pharmacy sales.

Brand Portfolio

GPT Healthcare, ILS Hospitals.

New Products/Services

New medical specialties at existing hospitals and the full-scale launch of the Raipur facility are expected to contribute significantly to the projected 8-10% EBITDA margin for new units in FY27.

Market Expansion

Expansion into Raipur (commissioned Q4 FY25) and Ranchi (planned for FY2027-28) to reduce geographic concentration in West Bengal.

Market Share & Ranking

Established market position in Eastern India; specific ranking not disclosed.

🌍 External Factors

Industry Trends

The industry is shifting toward asset-light models and increased insurance penetration. GPTHEALTH is positioning itself by expanding into underserved Tier-2 cities like Raipur and Ranchi.

Competitive Landscape

Faces intense competition from large national hospital chains entering the Eastern Indian market.

Competitive Moat

Moat is built on an established regional brand and strong internal cost controls resulting in RoCE of 23-30% in mature periods. Sustainability depends on maintaining high ARPOB and managing the ramp-up of new facilities.

Macro Economic Sensitivity

Sensitive to healthcare spending and insurance penetration. Ayushman Bharat expansion and GST exemptions on premiums are cited as vital enablers for growth.

Consumer Behavior

Shift toward organized healthcare and specialized treatments is driving higher out-patient volumes (89,802 in H1 FY26 vs 78,909 in H1 FY25).

Geopolitical Risks

Low direct impact, but global supply chain disruptions could affect the cost of imported medical equipment.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Clinical Establishment Acts and government-mandated price caps on cardiac stents, knee implants, and other essential medical devices.

Taxation Policy Impact

Effective tax rate was approximately 30% in H1 FY26 (INR 7.9 Cr tax on INR 26.2 Cr PBT).

⚠️ Risk Analysis

Key Uncertainties

Ramp-up time for the Raipur hospital poses a risk to consolidated profitability; a failure to reach 25% occupancy within 15 months could lead to sustained EBITDA losses.

Geographic Concentration Risk

High concentration with significant revenue derived from West Bengal and Tripura, making the company vulnerable to regional economic or regulatory shifts.